Goldman Sachs Lowers Price Target on Roche, Maintains Sell Recommendation

Goldman Sachs lowered its price target on Roche Holding AG (ROG.SW) to 230 Swiss Francs ($254.47) per share from 236 Swiss Francs per share before markets opened on Tuesday while maintaining a sell re

MT NewswiresJul 2 08:12 ET

Roche Holding AG (RHHVF) Receives a Hold From Jefferies

TipRanksJul 2 06:19 ET

Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs

Roche (RHHBY Quick QuoteRHHBY - Free Report) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a label expansion of ophthalmology drug Vabysmo (faricimab).

Zacks Jul 2 05:15 ET

Deutsche Numis Keeps Their Hold Rating on Roche Holding AG (RHHVF)

TipRanksJul 1 08:16 ET

Roche's (RHHBY.US) new generation antibody therapy has received a positive regulatory decision.

According to the news from the Witsight financial APP, Roche (RHHBY.US) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive view on its new generation of C5 cycle antibody Piasky (crovalimab) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). CHMP recommends that PiaSky be used in adults and adolescents (ages 12 and above and weighing at least 40 kg) who have not received C5 inhibitors or have received C5 inhibitors. If approved, PiaSky will be the first monthly therapy

Zhitong FinanceJun 30 20:52 ET

Roche's Vabysmo Gets CHMP Recommendation for Third Indication Retinal Vein Occlusion (RVO)

Yahoo FinanceJun 28 07:15 ET